[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493112":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":56,"collaborators":59,"id":63,"slug":26,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Connecticut","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MPL-rich dairy powder","EXPERIMENTAL","Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.",[13],"Drug: Milk Polar Lipid-Rich Dairy Powder",{"label":15,"type":16,"description":17,"interventionNames":18},"Control dairy powder","PLACEBO_COMPARATOR","Daily consumption of 50 g of dairy powder containing \\\u003C0.1 g MPL for 8 weeks",[19],"Dietary Supplement: Dairy Powder",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Milk Polar Lipid-Rich Dairy Powder","Effects of the addition of 6.5 g of milk polar lipids to dairy powder.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DIETARY_SUPPLEMENT","Dairy Powder","Effects of dairy control powder",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Christopher N Blesso, Ph.D.","CONTACT","860-486-9049","christopher.blesso@uconn.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Storrs","Connecticut","06269","United States",{"type":46,"coordinates":47},"Point",[48,49],-72.24952,41.80843,{"lat":49,"lon":48},[52,54],{"name":53,"role":35,"phone":26,"phoneExt":26,"email":37},"Christopher Blesso, Ph.D.",{"name":53,"role":55,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Christopher Blesso","Associate Professor",[60],{"name":61,"class":62},"Dairy Management Inc.","INDUSTRY","100493112",false,"NCT05700916","Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity","Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity","Inclusion Criteria:\n\n* LDL-C ≥ 130 mg\u002FdL\n* Waist circumference ≥ 88 cm for women, ≥ 102 cm for men\n* Aged 18 to 70 years\n\nExclusion Criteria:\n\n* Renal disease\n* Liver disease\n* Diabetes\n* Heart disease\n* Stroke\n* Cancer\n* Eating disorders\n* Thyroid disease\n* Gut-associated pathologies\n* Autoimmune diseases\n* Chronic inflammatory diseases\n* Scleroderma\n* Gallbladder disease\n* Blood clotting disorders\n* Intravenous drug use\n* Fasting plasma\u002Fserum triglycerides \\>500 mg\u002FdL\n* Fasting plasma\u002Fserum glucose \\>126 mg\u002Fd\n* Weight changes \\>10% over last 4 weeks\n* Oral antibiotics use up to 1 month prior to and during study\n* Allergy or intolerance to milk products\n* Taking lipid-lowering medications (e.g., statins, fibrates)\n* Taking anti-inflammatory medications (e.g., corticosteroids)\n* Taking medications which primarily affect blood clotting (e.g., warfarin).",true,"ALL","18 Years","70 Years",{"count":74,"type":75},130,"ESTIMATED","INTERVENTIONAL",[78],"EARLY_PHASE1","The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.",[81,82],"Dyslipidemias","Obesity","2025-12-15",{"date":85,"type":86},"2025-12-22","ACTUAL",{"date":88,"type":86},"2023-10-20",{"date":90,"type":75},"2026-06",{"name":5,"class":6},1]